MAP2K1 and neoplasm: KRAS was suggested as a biomarker for treatment with AZD6244 (Selumetinib), which is a MEK1 inhibitor [67], while another phase II clinical study identified that NF1 was also indicative of tumor response to AZD6244 [68].